NIQ Research Uncovers Hidden Consumer Attitudes Toward AI-Generated Ads
12.12.2024 15:00:00 CET | Business Wire | Press release
New research to be formally presented at 2025 Consumer Electronics Show (CES)
As Gen AI continues to push the boundaries of creative industries, NielsenIQ (NIQ), the world’s leading consumer intelligence company, unveiled groundbreaking new research on how the consumer brain processes AI-generated advertisements—with critical implications for advertisers navigating the opportunities and challenges of this emerging technology. NIQ will be speaking about these findings across generational considerations at the CES 2025 panel session, Adapting to Change: Demographic Shifts in Advertising Strategyon Thursday, January 9th at 10:00 a.m. PST.
Commenting on the findings, Ramon Melgarejo,President, Strategic Analytics & Insights at NIQ, said: “Brands and agencies are innovating at a rapid pace, leveraging AI-generated content in their advertising. They need to be cautious, as our study reveals that consumers are quite sensitive to the authenticity of ad creatives, both at the implicit (nonconscious) and explicit (conscious) levels. Brands must prioritize insights-led creative evaluation to produce effective ads.”
Key research on AI-generated ads finds:
- Negative brand halo
Consumers intuitively identified most of the AI-generated ads, perceiving them as less engaging and more “annoying,” “boring,” and “confusing” than traditional ads. These sentiments suggest that AI-generated ads may create a negative halo effect that could dampen consumer perceptions of both the ad and the brand. - Weak memory activation
AI-generated ads—even those perceived as “high quality”—elicited weaker memory activation in the brain, compared to traditional ads. This reaction suggests a misalignment between the content and existing memory structures—a gap that could impede consumers’ motivation to act. - Brand reinforcement pros and cons
By drawing from pre-existing visual and conceptual representations, AI-generated ads successfully reinforced existing brand associations. Coupled with the negative halo effect, however, this benefit could be outweighed by overall negative perceptions. - Cognitively taxing visuals
Low-quality visuals in AI-generated ads increase the cognitive effort required to process them, distracting from the intended message. High-quality execution is essential for effective storytelling and brand communication.
A Transformative Trend
“As advertisers experiment with generative AI to streamline ad creation and reduce costs, this research provides critical guardrails,” said Marta Cyhan-Bowles, Chief Communications Officer and Head of Global Marketing at NIQ. “Our neuroscience-driven approach reveals how consumers nonconsciously process AI-generated content and highlights the fine line between innovation and discomfort.”
Cyhan-Bowles cautions that while AI offers exciting potential for early-stage ideation and brand asset testing, poorly executed AI content can harm brand equity. Although this emerging technology may not immediately replace traditional ad creation, its capabilities can still enhance creative processes when thoughtfully integrated.
AI is also driving marketing efficiencies in long-term consumer-focused product development, offering deeper insights into customer preferences. It is closing the gap between businesses and customers by enhancing the understanding of consumer preferences. Groundbreaking tools like NIQ’s Ad Explorer are helping marketers improve brand equity by leveraging nonconscious consumer perceptions to prioritize creative insights, test multiple ad iterations, and meet deadlines without sacrificing quality.
Read more about the detailed study here and stay informed on future developments in AI-generated advertising.
About NIQ
NielsenIQ (NIQ) is the world’s leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. NIQ combined with GfK in 2023, bringing together the two industry leaders with unparalleled global reach. Today NIQ has operations in more than 95 countries covering 97% of GDP. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full View™.
For more information, please visit www.niq.com.
About NIQ Study
The study involved more than 2,000 participants watching a series of low- to high-quality AI-generated ads. Brain activity was measured using electroencephalogram (EEG) for approximately 150 of those participants. After viewing the ads, all participants were asked to share explicit feedback via survey.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241212354811/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom